Radius Health, Inc. (NASDAQ:RDUS) – Stock analysts at Cantor Fitzgerald issued their FY2016 EPS estimates for shares of Radius Health in a note issued to investors on Tuesday. Cantor Fitzgerald analyst M. Goldstein expects that the firm will earn ($4.13) per share for the year. Cantor Fitzgerald currently has a “Buy” rating and a $70.00 target price on the stock. Cantor Fitzgerald also issued estimates for Radius Health’s FY2017 earnings at ($2.57) EPS.

Other equities research analysts have also recently issued research reports about the company. Zacks Investment Research cut Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 4th. Canaccord Genuity set a $85.00 target price on Radius Health and gave the stock a “buy” rating in a research note on Wednesday, September 28th. HC Wainwright boosted their target price on Radius Health from $55.00 to $71.00 and gave the stock a “buy” rating in a research note on Wednesday, September 21st. Jefferies Group restated a “hold” rating and set a $46.00 target price on shares of Radius Health in a research note on Tuesday, September 20th. Finally, Cowen and Company restated a “buy” rating on shares of Radius Health in a research note on Wednesday, September 28th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $61.50.

Earnings History and Estimates for Radius Health (NASDAQ:RDUS)

ILLEGAL ACTIVITY WARNING: “Radius Health, Inc. Forecasted to Post FY2016 Earnings of ($4.13) Per Share (RDUS)” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this report can be viewed at http://www.watchlistnews.com/radius-health-inc-forecasted-to-post-fy2016-earnings-of-4-13-per-share-rdus/1061055.html.

Shares of Radius Health (NASDAQ:RDUS) opened at 45.46 on Friday. Radius Health has a 52-week low of $24.75 and a 52-week high of $59.88. The firm has a 50-day moving average price of $45.47 and a 200 day moving average price of $48.19. The stock’s market cap is $1.96 billion.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.03) by $0.04. During the same period last year, the firm posted ($0.68) earnings per share.

ILLEGAL ACTIVITY WARNING: “Radius Health, Inc. Forecasted to Post FY2016 Earnings of ($4.13) Per Share (RDUS)” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this report can be viewed at http://www.watchlistnews.com/radius-health-inc-forecasted-to-post-fy2016-earnings-of-4-13-per-share-rdus/1061055.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Arrowgrass Capital Partners US LP bought a new position in Radius Health during the third quarter worth about $32,342,000. Fiera Capital Corp bought a new position in Radius Health during the second quarter worth about $21,097,000. Price T Rowe Associates Inc. MD raised its position in Radius Health by 78.7% in the third quarter. Price T Rowe Associates Inc. MD now owns 1,052,018 shares of the biopharmaceutical company’s stock worth $56,904,000 after buying an additional 463,447 shares during the last quarter. Vanguard Group Inc. raised its position in Radius Health by 13.5% in the second quarter. Vanguard Group Inc. now owns 2,615,168 shares of the biopharmaceutical company’s stock worth $96,107,000 after buying an additional 311,547 shares during the last quarter. Finally, Farallon Capital Management LLC raised its position in Radius Health by 22.4% in the second quarter. Farallon Capital Management LLC now owns 1,535,000 shares of the biopharmaceutical company’s stock worth $56,411,000 after buying an additional 281,305 shares during the last quarter. 96.48% of the stock is currently owned by institutional investors and hedge funds.

About Radius Health

Radius Health, Inc is a biopharmaceutical company focused on developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Its product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase III development for use in the reduction of fracture risk in postmenopausal women with osteoporosis.

5 Day Chart for NASDAQ:RDUS

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.